Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	16.15B
Revenue (ttm)	6.11B
Net Income (ttm)	769.95M
Shares Out	501.47M
EPS (ttm)	1.58
PE Ratio	20.39
Forward PE	n/a
Dividend	0.55 (1.69%)
Ex-Dividend Date	Jul 11, 2025

Volume	584,560
Average Volume	808,484
Open	32.30
Previous Close	32.30
Day's Range	32.10 - 32.40
52-Week Range	26.28 - 39.80
Beta	-0.05
RSI	43.45
Earnings Date	Nov 11, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2024, Synmosa Biopharma's revenue was 5.55 billion, an increase of 7.96% compared to the previous year's 5.14 billion. Earnings were 684.68 million, an increase of 15.11%.